Gene · 3003
NIH grants2,103
NIH grants whose papers are about the gene, through NIH's grant-paper links.
1,021 to 1,040 of 2,103
Download this page as JSON| Grant | Title | GZMK papers | Newest fiscal year |
|---|---|---|---|
| R01CA016303 | Hormonal Regulation of Breast Cancer | 1 | 2022 |
| R01CA078831 | Epigenetic regulation by tumor suppressor p53 | 1 | 2022 |
| R01CA101795 | Novel Strategies for Intervention of Inflammatory Diseases and Cancer | 1 | 2022 |
| R01CA167291 | Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations | 1 | 2022 |
| R01CA173636 | Role of TET2 mutations in malignant transformation and acute myeloid leukemia | 1 | 2022 |
| R01CA217169 | BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinoma | 1 | 2022 |
| R01CA218579 | Single Cell Genome-Wide Myeloid Response Profiling in Immunotherapy | 1 | 2022 |
| R01CA220238 | Multi-omic analysis of Myc-driven splicing for prostate cancer therapeutic development | 1 | 2022 |
| R01CA222170 | Mechanisms of BET bromodomain metabolic reprogramming in triple negative breast cancer | 1 | 2022 |
| R01CA222203 | Fecal Microbiota Transplant and PD-1 blockade in Melanoma | 1 | 2022 |
| R01CA223150 | In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices | 1 | 2022 |
| R01CA226746 | Mechanisms of targeting cellular self-renewal in glioblastoma | 1 | 2022 |
| R01CA226802 | Unbiased identification of spliceosome vulnerabilities across cancer | 1 | 2022 |
| R01CA227237 | (PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactions | 1 | 2022 |
| R01CA227388 | Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors | 1 | 2022 |
| R01CA227473 | (8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors | 1 | 2022 |
| R01CA228181 | Targeting TIGIT and PD-1 in Melanoma | 1 | 2022 |
| R01CA229803 | Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer | 1 | 2022 |
| R01CA231112 | (PQ4) Novel tools for in vivo study of genetic interactions in cancer progression | 1 | 2022 |
| R01DE027736 | Immunotherapeutic responses to neoantigens in head and neck cancer | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3003/grants?page=52